Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like Peptide 1 receptor deficiency

HE Wilson-Pérez, AP Chambers, KK Ryan, B Li… - Diabetes, 2013 - Am Diabetes Assoc
HE Wilson-Pérez, AP Chambers, KK Ryan, B Li, DA Sandoval, D Stoffers, DJ Drucker
Diabetes, 2013Am Diabetes Assoc
Glucagon-like peptide 1 (GLP-1) is a peptide hormone that is released from the gut in
response to nutrient ingestion and that has a range of metabolic effects, including enhancing
insulin secretion and decreasing food intake. Postprandial GLP-1 secretion is greatly
enhanced in rats and humans after some bariatric procedures, including vertical sleeve
gastrectomy (VSG), and has been widely hypothesized to contribute to reduced intake,
weight loss, and the improvements in glucose homeostasis after VSG. We tested this …
Glucagon-like peptide 1 (GLP-1) is a peptide hormone that is released from the gut in response to nutrient ingestion and that has a range of metabolic effects, including enhancing insulin secretion and decreasing food intake. Postprandial GLP-1 secretion is greatly enhanced in rats and humans after some bariatric procedures, including vertical sleeve gastrectomy (VSG), and has been widely hypothesized to contribute to reduced intake, weight loss, and the improvements in glucose homeostasis after VSG. We tested this hypothesis using two separate models of GLP-1 receptor deficiency. We found that VSG-operated GLP-1 receptor–deficient mice responded similarly to wild-type controls in terms of body weight and body fat loss, improved glucose tolerance, food intake reduction, and altered food selection. These data demonstrate that GLP-1 receptor activity is not necessary for the metabolic improvements induced by VSG surgery.
Am Diabetes Assoc